Empagliflozin (SGLT-2i)

Dr. McPhee: This is not quite the best option in this case. Empagliflozin can an excellent drug, particularly for patients with certain co-morbidities, such as heart failure, chronic kidney disease, and established or high atherosclerotic cardiovascular (ASCVD) risk. It can also help when weight loss is a goal. There is no compelling cardiorenal indication to start it ahead of another drug that is more cost-effective and could also provide benefits in preventing complications and reducing weight.

Please go back and reconsider.

  • Presentation

Map: Michael Green_ORU (1141)
Node: 21950
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway

  • The Cultural Collision: Santet vs. Science
  • Propylthiouracil (Thioureylene)
  • Propranolol (Beta blocker)
  • Iodine (isotope 131)
  • Metformin (Biguanide)
  • Empagliflozin (SGLT-2i)
  • The Cultural Collision: Santet vs. Science
  • Glimepiride (sulfonyurea)
  • First
  • Empagliflozin
  • Pioglitazone
  • Metformin
  • Insulin
  • First
  • First
  • Empagliflozin
  • Presentation
  • Increased secretion of insulin from the pancreas
  • Presentation
  • Decreased entry of glucose into muscle cells
  • Decreased production of glucose from the liver
  • Decreased production of glucose from the liver
  • Increased entry of fatty acids into adipocytes
  • Presentation
  • Increased entry of fatty acids into adipocytes
  • Decreased entry of glucose into muscle cells
  • Decision: Initial Approach
  • Increased secretion of insulin from the pancreas
  • The Setting: Isolation and Responsibility
  • Second
  • Glipizide
  • Insulin
  • Pioglitazone
  • Metformin
  • Pioglitazone
  • Metformin (Biguanide)
  • Methimazole (Thioureylene)
  • Empagliflozin (SGLT-2i)

Reminder

empty_reminder_msg

FINISH

Time is up